The first rapid acting insulin biosimilar of NovoRapid® approved in the UK and EU1
Trurapi® was granted marketing authorization in the United Kingdom and is anticipated to be available to prescribe in England, Scotland and Wales in July.
Learn from other payors, consultants and diabetes specialist nurses how they adopted a rapid acting insulin biosimilar in their region.
These videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.
Dr Duncan Browne
Consultant Endocrinologist and Researcher Royal Cornwall Hospitals NHS Foundation Trust
Diabetes Specialist Nurse Cornwall Partnership NHS Foundation Trust
Formulary Pharmacist Gloucestershire Hospitals NHS Foundation Trust
Find useful resources such as formulary FAQ, leave pieces and videos for payors and healthcare professionals to support a positive rapid acting insulin biosimilar adoption
EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.
- Trurapi SmPC (April 2021)
- Data on File, MAT-GB-2101599 (v1.0) April 2021
- Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
- Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.